Xos (NASDAQ: XOS) launches $20M at-the-market stock offering program

Rhea-AI Filing Summary

Xos, Inc. entered into a Sales Agreement with Roth Capital Partners that allows it to offer and sell up to $20 million of common stock through an at-the-market program. Under current Form S-3 limitations, the company can sell up to $5,367,542 pursuant to this agreement.

Roth Capital Partners will act as sales agent and receive a 3.0% commission on gross proceeds from any share sales. Xos plans to use net proceeds for working capital, servicing debt, and general corporate purposes, including mandatory payments under its Second Amended and Restated Convertible Promissory Note.

false 0001819493 0001819493 2025-08-14 2025-08-14 0001819493 XOS:CommonStockParValue0.0001PerShareMember 2025-08-14 2025-08-14 0001819493 XOS:WarrantsEveryThirtyWarrantsExercisableForOneShareOfCommonStockAtExercisePriceOf345.00PerShareMember 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

XOS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-39598		98-1550505
(State or Other Jurisdiction of  Incorporation or  Organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

3559 Tyburn Street, Los Angeles, California		90065
(Address of Principal Executive Offices)		(Zip Code)

(818) 316-1890

(Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		XOS		Nasdaq Capital Market
Warrants, every thirty warrants exercisable for one share of Common Stock at an exercise price of $345.00 per share		XOSWW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On August 14, 2025, Xos, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Roth Capital Partners, LLC (the “Agent”). Pursuant to the terms of the Sales Agreement, the Company may offer and sell shares of the Company’s common stock, par value $0.0001 (the “Shares”) having an aggregate offering amount of up to $20 million from time to time through the Agent. Pursuant to General Instruction I.B.6 of Form S-3, the Company can currently only sell up to $5,367,542 pursuant to the Sales Agreement. The Agent will use its commercially reasonable efforts, as the agent and subject to the terms of the Sales Agreement, to sell the Shares offered. Sales of the Shares, if any, may be made in sales deemed to be an “at-the-market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. The Agent will be entitled to a commission from the Company of 3.0% of the gross proceeds from the sale of Shares sold under the Sales Agreement. In addition, the Company has agreed to reimburse certain expenses incurred by the Agent in connection with the offering. The Company intends to use any net proceeds from the offering for working capital, debt servicing and general corporate purposes, including any mandatory payments pursuant to the terms of our Second Amended and Restated Convertible Promissory Note.

The Shares will be sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-272284), that was filed with the Securities and Exchange Commission, including the related prospectus, dated June 8, 2023, as supplemented by a prospectus supplement. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

The Sales Agreement contains customary representations, warranties, and agreements of the Company and the Agent, indemnification rights and obligations of the parties and termination provisions. The Sales Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K, and the description of the Sales Agreement in this Item 1.01 is qualified in its entirety by reference to such exhibit.

A copy of the opinion of Proskauer Rose LLP relating to the legality of the Shares is filed as Exhibit 5.1 to this Current Report. 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
1.1		Sales Agreement, dated as of August 14, 2025, between Xos, Inc. and Roth Capital Partners, LLC
5.1		Opinion of Proskauer Rose LLP
23.1		Consent of Proskauer Rose LLP (included in Exhibit 5.1 hereto)
104		Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	XOS, INC.
	(Registrant)
Date: August 14, 2025	By:	/s/ Liana Pogosyan
		Liana Pogosyan
		Chief Financial Officer

2

FAQ

What did XOS disclose in this 8-K filing?

XOS, Inc. disclosed that it entered into a Sales Agreement with Roth Capital Partners, LLC to sell shares of its common stock through an at-the-market offering program.

How much stock can XOS sell under the new at-the-market program?

The Sales Agreement permits XOS to offer and sell up to $20 million of its common stock, with a current Form S-3 capacity limitation of $5,367,542.

Who is the sales agent for the XOS at-the-market offering and what is the fee?

Roth Capital Partners, LLC will act as the sales agent and is entitled to a 3.0% commission on the gross proceeds from any shares sold under the Sales Agreement.

How does XOS (XOS) plan to use the proceeds from the stock sales?

XOS intends to use any net proceeds for working capital, debt servicing, and general corporate purposes, including mandatory payments under its Second Amended and Restated Convertible Promissory Note.

Under what registration statement will the XOS shares be sold?

The shares will be sold under XOS’s shelf registration statement on Form S-3 (File No. 333-272284), using the related base prospectus and a prospectus supplement.

Is the XOS at-the-market offering a firm commitment to sell all $20 million of shares?

No. The agreement allows XOS to sell shares from time to time in at-the-market transactions up to $20 million, subject to the current $5,367,542 capacity, but does not require that any specific amount be sold.